Literature DB >> 8370929

Characterization of monoclonal antibodies specific for the V beta 3 family of the human T cell receptor generated using soluble TCR beta-chain.

S D Calaman1, G R Carson, L D Henry, J S Kubinec, R E Kuestner, A Ahmed, E M Wilson, A Y Lin, C W Rittershaus, H C Marsh.   

Abstract

A soluble, recombinant form of the human T cell receptor (TCR) beta-chain containing the V beta 3.1 sequence has been constructed, expressed in Chinese hamster ovary cells, amplified by dihydrofolate reductase selection, and purified in quantities appropriate for the generation of monoclonal antibodies (mAb). The V beta 3 sequence was chosen because of its reported elevated usage in the synovial T cells of rheumatoid arthritis patients but the approach described should be applicable to other known human V beta gene sequences. By this method, two mAb were prepared which reacted with up to 10% of normal, live peripheral blood T cells but with reactivity varying greatly among individual donors. Both mAb specifically bound to a murine T cell line transfected with a human TCR V beta 3.1 and immunoprecipitated a protein of the expected molecular weight for the TCR beta-chain. Both antibodies were mitogenic for T cells and analysis of peripheral blood lymphocyte cultures stimulated with the mAb suggested that both were specific for the V beta 3.1 subfamily and not D beta or J beta. Clones expressing V beta 3, which were derived from mAb-stimulated peripheral blood lymphocytes of a single individual, preferentially (8/13), but not exclusively, utilized the J beta 2.7 gene segment. The V beta 3.1 usage showed no preference for the CD8+ or CD4+ subpopulations of normal peripheral blood T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370929     DOI: 10.1016/0022-1759(93)90316-y

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  1 in total

1.  Genetic analysis of low V beta 3 expression in humans.

Authors:  J P Donahue; N S Ricalton; C E Behrendt; C Rittershaus; S Calaman; P Marrack; J W Kappler; B L Kotzin
Journal:  J Exp Med       Date:  1994-05-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.